Changes in TGF-beta mRNA in Breast Cancer Patients on Tamoxifen
Author Information
Author(s): J MacCallum, JC Keen, JMS Bartlett, AM Thompson, JM Dixon, WR Miller
Primary Institution: University Department of Surgery, Edinburgh Royal Infirmary
Hypothesis
Does tamoxifen therapy affect the expression of TGF-beta isoforms in breast cancer patients?
Conclusion
The study suggests that response to tamoxifen therapy may be associated with an increase in expression of specific TGF-beta isoforms in some tumours.
Supporting Evidence
- All patients had tumours larger than 3 cm and were ER-rich.
- 27 out of 37 patients responded to tamoxifen treatment.
- Significant correlation was found between TGF-beta2 expression and treatment response.
Takeaway
This study looked at how a medicine called tamoxifen affects certain proteins in breast cancer. It found that some patients showed changes in these proteins when treated.
Methodology
Tumour samples were taken from patients before and during tamoxifen treatment, and mRNA levels of TGF-beta isoforms were assessed.
Limitations
The study did not find a general increase in TGF-beta expression with tamoxifen treatment, and results may vary due to tumour heterogeneity.
Participant Demographics
Patients were over 70 years old with oestrogen receptor-positive breast cancer.
Statistical Information
P-Value
0.018
Statistical Significance
p=0.018
Want to read the original?
Access the complete publication on the publisher's website